


2016 Spring ADC Directors Meeting: Scientific Symposium









Advancing the Clinical Science of Dementia: Not Just Your Grandfather's Assessment

Jeffrey Kaye, MD
Layton Professor of Neurology & Biomedical Engineering
Oregon Center for Aging & Technology
NIA - Layton Aging & Alzheimer's Disease Center
kaye@ohsu.edu





The fundamental limitation of current research... The ability to detect meaningful change.

Cardinal features of change - slow decline punctuated with acute, unpredictable events - are challenging to assess with legacy tools and methods.














Example of challenge of detecting change with

current data:
Variability in
baseline and
progression
of cognitive
tests (ADNI
data from
Dodge et. al.,
2014)






Challenge of Detecting Change: Self Report Inaccuracy

Are you sure?: Lapses in Self-Reported Activities Among Healthy Older Adults Reporting Online. Wild et al., 2015

"What were you doing during the past 2 hours?" n=95; Mean age 84 yrs



- 26% No Match Between Sensors & Report
- 49% Partial Agreement
- 25% Full Match



Area Firing	s Time	<u>.</u>
Kitchen 1	1	0:00:00
Bedroom 1	14	0:01:52
Kitchen 1	1	0:00:00
Living Room 1	3	0:00:22
Living Room 1	1	0:00:00
Bathroom 2	1	0:00:00
Living Room 1	1	0:00:00
Kitchen 1	1	0:00:00
Bedroom 1	4	0:01:12
Kitchen 1	5	0:00:33
Living Room 1	1	0:00:00
Kitchen 1	1	0:00:00
Living Room 1	1	0:00:00
Kitchen 1	1	0:00:00
Bedroom 1	1	0:00:00
Kitchen 1	1	0:00:00
Bedroom 1	1	0:00:00
Kitchen 1	10	0:01:03
Living Room 1	1	0:00:00
Kitchen 1	1	0:00:00
Living Room 1	1	0:00:00
Computer Room	3	0:00:14

The Changing Clinical Research Paradigm





- Brief
- Episodic
- Clinic-based
- Subjective
- Obtrusive
- Inconvenient





- Pervasive Computing
- Wireless Technologies
- "Big Data Analytics"





- Real-time
- Continuous
- Home-based
- Objective
- Unobtrusive
- Ambient








- New Observations & Discovery
- Maximally Effective Clinical Research
- Useful & Trusted Products & Services
- Better Outcomes for Patients & Families






Improving detection of change: The case for continuous, objective, measures



- More data points →
- More accurate estimates of trajectories (slopes over time)
- Earlier detection of change







Many ways to approach/collect data using pervasive computing and "digital biomarkers"

 Domain (genetic, environmental, clinical); frequency (episodic, continuous); certainty (supervised, unsupervised); method of capture (device, procedure); locus of capture (home, work, hospital)



"Resist the law of the hammer"

 In a growing diverse IoT, connected world, less focus on devices to be used; more on when, where, and how to practically and reliably capture longitudinal data.








Technology 'Agnostic' Pervasive Computing Platform: *The Life Laboratory*






Identifying prodromal MCI



Differentiation of early MCI: Total Activity & Walking




Activity patterns associated with mild cognitive impairment

Hayes et al. Alzheimers Dement, 2008


Trajectories of walking speed over time

Dodge, et al. Neurology, 2012






Early MCI - "high variability at baseline, then decreasing over time" Late MCI - "low variability and declining"




Differentiation of MCI:Night-time Behavior & Sleep


Normal -

NA-MCI -









Objective Measure	Intact	aMCI	naMCl	P value
Movement in Bed (sensor firings)	9.4 ± 0.4	7.8 ± 0.9	10.9 ± 0.7	p < 0.05 (aMCl < naMCl)
Wake After Sleep Onset (mins)	27.2 ± 1.2	13.5 ± 2.6	20.6 ± 2.0	p < 0.001 (aMCl < intact, naMCl)
Settling Time (mins)	2.5 ± 0.07	2.3 ± 0.15	3.1 ± 0.11	p < 0.001 (naMCI > intact, aMCI)
Times up at night (# times)	2.1 ± 0.04	1.6 ± 0.10	1.9 ± 0.08	p < 0.001 (aMCl < intact, naMCl)
Total Sleep Time (hrs)	8.3 ± 0.04	8.5 ± 0.09	8.5 ± 0.07	NS

	No Di	fferen	ces Between	Groups in Se	elf-Report M	easures
i	0 10 0					

Self-Report Measure	Intact	aMCl	naMCI	P value
Subjective Daytime Sleepiness	1.8 ± 0.2	1.5 ± 0.3	2.0 ± 0.3	0.69
Subjective Insomnia	1.3 ± 0.2	0.8 ± 0.3	1.6 ± 0.3	0.21
Subjective Restlessness	1.0 ± 0.1	0.4 ± 0.3	0.7 ± 0.2	0.34
Times up at night	1.1 ± 0.1	1.0 ± 0.3	1.0 ± 0.2	0.77


Hayes, et al. Alzheimer Dis Assoc Disord. 2014 Hayes, et al. IEEE Eng Med Biol Soc, 2010

Every Day Cognition: Medication adherence as a measure of cognitive function




- Adherence assessed continuously x 5 wks with MedTracker taking a
- Mean Age 83 yrs
- Based on ADAScog: Lower Cognition Group vs Higher Cognition Group

Hayes et al., *Proceedings : Engineering in Medicine and Biology Soc*, 2006; Leen, et al., *Technology and Aging*, 2007; Hayes et al. *Journal of Aging Health*, 2009; Hayes et al. *Telemedicine Journal and E-Health*. 2009





Individual patterns of medication adherence over time






Every Day Cognition: Computer use changes over time in MCI (without formal cognitive tests)







- At Baseline: Mean
 1.5 hours on
 computer/per day
- Over time:
 - Less use days per month
 - Less use time when in session
 - More variable in use pattern over time





Dyad Analysis




Figure. Spiral plot (**A**) depicting the within home location of a husband and wife plotted on a 24 hour clock for 6 consecutive days using a Bluetooth beacon system (**B** - photo of one of the beacons deployed around the home) paired with smartwatches (**C**) for individual localization. Each concentric circle outward depicts one day. In **A**, the colors represent where the person is located (see key). The outer trace is the husband, inner trace is the wife and middle trace is the activity of PIR sensors (see inset).



Self-Report Data will Always be Needed...

...If captured on-line may provide measures of cognitive







Figure 3: Screen shot showing questions presented for the weekly personal health and activity record (or PHAR) on a mobile device. "Yes" responses result in a drop-down menu that asks for further detail. The survey is tracked for timing of each item response and total time to complete the survey each week.



Seelye et al., Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2015 Seelye et al., Alzheimer's Disease & Assoc. Disorders, 2015

Some Use Cases...




Applications Toward Advancing Clinical Care...

Internet searches to identify memory

concerned patients

Dataset represents an average of 385 days of continuous computer search data (min 67 days, max 601 days) from 77 participants completing 8,899 searches (in Bing, Google and Yahoo)


- Courtesy of J. Austin







Teledementia Care: Direct to Home

Alzheimer's Care via Telemedicine for Oregon (ACT-ON) Phase I: Establishing the Reliability of Telemedicine-based Measures (PIs – A. Lindauer and D. Erten-Lyons)
















Advancing Clinical Trials...

The First RCT?



James Lind, 1774



cancergrace.org: S. Ramalingham

RCT to Increase Social Interaction in MCI Using Home-based Technologies (PI: H. Dodge)

- 6 week RCT of daily 30 min video chats
- 89% of all possible sessions completed;
 Exceptional adherence no drop-out
- Intervention group improved on executive/ fluency measure.
- MCI participants spoke 2985 words on average while cognitively intact spoke 2423 words during sessions; better discrimination of MCI than conventional tests (animal fluency and delayed list recall)













SHARP: Multi-modal Brain Health Program



KILLINGSWORTH CT WYGAN BLANDENA ST SKIDMOR ST HUMBOLDT PI: Raina Croff



Predictive Modeling Using Multi-Dimensional Data




Predictive Modeling Using Multi-Dimensional Data: High dimensional data fusion model predicting MCI

49,992,645 observations **Context:** Weather, Consumer Confidence Index, etc. 24/7 Behavioral -**Activity Data:** Computer use, time out of Outcome home, etc. **MCI** Model **Weekly Self-Report: Transition** Mood, Pain, Falls, ER Visits, Visitors, etc... Intervention Research **Assessments:** Cognition, Physical Function, Genetics, Biomarkers, etc. **Health Records:** EHR, Pharmacy, Home Care, etc.



Predicting MCI Transitions: Sensitivity Analysis

 Likelihood of a MCI transition within the next 24 months – ROC AUC under curve= 0.95




Model Fit & ROC/AUC Results			
Model	AUC (SD)		
Behavior 1	0.85 (0.004)		
Behavior 2	0.85 (0.004)		
Clinical	0.88 (0.004)		
Full	0.95 (0.002)		





Identifying Drug Class Effects: Drug Action Behavioral

Fingerprinting Example of analgesics



	NSAID	Opioid	Both
Sensitivity (%)	94.9	65.9	67.4
Specificity (%)	99.9	98.6	99.6
Positive Predictive Value (%)	99.7	82.6	86.1
Negative Predictive Value (%)	99.7	96.6	98.9
Correctly Classified (%)	99.6	95.6	98.6

Logistic regression models treated as classifiers (and model fit statistics)



Behavioral Fingerprinting by Treatment Status



Values are odds ratios. 1 is the reference value, and is 'normalized' to placebo.





Transforming Clinical Trials with High Frequency, Objective, Continuous Data: "Big Data" for Each Subject

MCI Prevention Trial – Sample Size Estimates

	Current Method	Continuous Measures	
	LM Delayed Recall*	Computer Use**	Walking Speed**
SAMPLE SIZE TO SHOW 50% EFFECT	688	10	94
SAMPLE SIZE TO SHOW 40% EFFECT	1076	16	148
SAMPLE SIZE TO SHOW 30% EFFECT	1912	26	262
SAMPLE SIZE TO SHOW 20% EFFECT	4300	58	588

- Reduces required sample size and/or time to identify meaningful change.
- Reduces exposure to harm (fewer needed/ fewer exposed)
- More precise estimates of the trajectory of change; allows for intra-individual predictions.
- Provides the opportunity to substantially improve efficiency and inform go/nogo decisions of trials.

New Generation High Efficiency Clinical Trials

6 months

Traditional Trial Further Efficient Longitudinal Enrichment: Enrichment: Assessment: Stratification according Stratification according Continuously assessed to increased risk of AD. to who will progress. objective measures. Can predict Does not predict Detects individual relevant who progresses who progresses change rapidly Biomarker **Behavioral** Continuous **Enrichment** Phenotype **Assessment** Imaging, CSF, Plasma, **Enrichment** Computer use, Genetics, Sleep hygiene, Walking speed, other risk factors Time out of home, Activity, Mobility, etc... etc... Continuous **Disease Progression Population AD Pathology AD Pathology** Assessment: **Precision Phenotyped** Group(s) Group Group **AD Progression**

2-3 months

6 months

Acknowledgements

"The smallest act of kindness is worth more than the grandest intention."

- Oscar Wilde

Profound Thanks to My Amazing
Colleagues and the Research Volunteers



Funders



alzheimer's Ω 5 association














































Thank You!



"This really is an innovative approach, but I'm afraid we can't consider it. It's never been done before."



